Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | RET | P07949 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | LTK | P29376 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | PRKX | P51817 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21863628 | 0.81 | GLA (0.58) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL7571385 | 0.78 | GLA (0.55) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL13219428 | 0.78 | L3MBTL1 (1.00) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL11577556 | 0.77 | GLA (0.54) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL27762041 | 0.77 | GLA (0.54) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL29520983 | 0.77 | GLA (0.54) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL655480 | 0.74 | NOS1 (0.59) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL29561070 | 0.74 | NOS1 (0.59) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL11888514 | 0.73 | HDAC6 (0.66) | GLAL3MBTL1NOS1RETCDK5 | |
| SCHEMBL3658627 | 0.73 | GLA (0.50) | GLAL3MBTL1NOS1RETCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4442318-A2 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2022-08-11 | — | — | US | disclosed |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | Vettore, LLC (US) | 2022-04-05 | — | — | US | disclosed |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2019-04-18 | — | — | US | disclosed |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492171-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | GLA 3395/4885L3MBTL1 4608/4885NOS1 2896/4885 |
| US-11292767-B2 | Heterocyclic inhibitors of MCT4 | SLC16A3, SLC16A1, MCTS1 | GLA 3395/4885L3MBTL1 4608/4885NOS1 2896/4885 |
| US-20190112275-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | GLA 3395/4885L3MBTL1 4608/4885NOS1 2896/4885 |
| US-20220251047-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | GLA 3395/4885L3MBTL1 4608/4885NOS1 2896/4885 |
| US-20180162822-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A3, SLC16A1, MCTS1 | GLA 3395/4885L3MBTL1 4608/4885NOS1 2896/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | GLA 4808/4885L3MBTL1 3646/4885NOS1 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.